MedPath

Causes and Natural History of Dyslipidemias

Recruiting
Conditions
Hypercholesterolemia
Atherosclerosis
Registration Number
NCT00353782
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
2000
Inclusion Criteria

INCLUSION CRITERIA:<br><br> - Children >= 2 years of age and >12 kg and adults<br><br> - Dyslipidemia subjects of interest the group<br><br>The following is a representative list of the types of patient presentations with<br>dyslipidemia and potential diagnoses eligible for this protocol:<br><br> - Plasma cholesterol levels >200 mg/dl or <120 mg/dl includes patients with diagnoses<br> such as familial hypercholesterolemia, familial combined hyperlipidemia,<br> sitosterolemia, lipoprotein lipase, hepatic lipase or apo-CII deficiency, and<br> dysbetalipoproteinemia.<br><br> - Plasma LDL-C levels >130 mg/dl or <70 mg/dl includes patients with diagnoses such as<br> familial hypercholesterolemia, PCSK9, apo3500, familial combined hyperlipidemia,<br> sitosterolemia, dysbetalipoproteinemia, abetalipoproteinemia and<br> hypobetalipoproteinemia.<br><br> - Plasma HDL-C levels >70 mg/dl or <25 mg/dl includes patients with deficiency of<br> cholesteryl ester transfer protein, lecithin cholesterol acyltransferase,<br> phospholipid transfer protein, lipoprotein lipase, hepatic lipase, or apo-CII,<br> ANGPTL3, and Tangier disease.<br><br> - Plasma triglyceride levels >150 mg/dl includes patients with deficiency of<br> lipoprotein lipase, hepatic lipase or apoC-II, GPIHBP1, LMF1,<br> dysbetalipoproteinemia, Type I, Type IV and Type V hyperlipidemia.

Exclusion Criteria

Not provided

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
permit a full evaluation of the lipoproteins, apolipoproteins, and cellular enzymes and receptors relevant to lipoprotein metabolism in order to accurately diagnose and treat patients with potential genetic defects in these processes
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath